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Background: The purpose of this work is to report our experience using loteprednol 0.5% 
for routine prophylaxis after photorefractive keratectomy in an academic refractive surgery 
center.
Materials and methods: Photorefractive keratectomy was performed on 579 eyes from 
316 patients in this retrospective chart review of patients treated postoperatively with either 
fluorometholone 0.1% (273 eyes) or loteprednol 0.5% (306 eyes). Primary outcome measures 
at 6 months included uncorrected distance visual acuity, corrected distance visual acuity, and 
manifest refraction spherical equivalent. Secondary outcome measures were incidence of corneal 
haze and increased intraocular pressure.
Results: There were no statistically significant differences in preoperative characteristics 
between the two groups when comparing age, sex, best-corrected visual acuity, spherical equiva-
lent, or keratometry. Both groups achieved excellent visual outcomes, with a mean uncorrected 
distance visual acuity (logMAR) of 0.004 ± 1.4 in the fluorometholone group and −0.028 ± 1.1 in 
the loteprednol group (P = 0.013) at 6 months. Postoperative corneal haze and increased intraocu-
lar pressure were uncommon and not statistically different between the groups.
Conclusion: Loteprednol 0.5% performed similarly to fluorometholone 0.1% when used 
for prophylaxis following photorefractive keratectomy. The incidence of haze and increased 
intraocular pressure were similar between the two groups.
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Introduction
Excimer laser photoablation sculpts corneal tissue to correct refractive error during 
photorefractive keratectomy. Corneal haze is a well known and potentially vision-
threatening complication of photorefractive keratectomy. Topical ophthalmic corti-
costeroids are routinely prescribed postoperatively by most surgeons to prevent this 
complication, but these medications may pose other risks, such as elevated intraocular 
pressure and cataract formation. The benefit of using topical corticosteroids to prevent 
haze is controversial,1,2 but some studies have demonstrated a decreased incidence of 
haze with corticosteroid use.3,4
Desirable characteristics for prophylactic topical steroids to be used in photo-
refractive keratectomy include effective modulation of the healing response to pre-
vent corneal haze while at the same time minimizing side effects, such as elevated 
intraocular pressure or cataract formation. Loteprednol etabonate is a corticosteroid 
that exerts its therapeutic effects and is then quickly changed into inactive metabolites 
by nonspecific esterases found in the cornea.5 The faster metabolism of loteprednol 
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is believed to give it a lower side effect profile than other 
steroids, having a smaller effect on intraocular pressure.6,7 
This retrospective study compares outcomes of loteprednol 
0.5% versus fluorometholone 0.1% used postoperatively in 
patients undergoing photorefractive keratectomy.
Materials and methods
Institutional review board approval was obtained and 
a retrospective chart review of patients who received 
photorefractive keratectomy surgery at the Moran Eye 
Center between January 2005 and May 2010 was performed. 
Complete 6-month follow-up data were available for 579 
eyes from 316 patients. Two surgeons (MDM, MM) 
performed the photorefractive keratectomy surgery and 
the patients were divided into two groups depending on 
the postoperative steroid medications used, ie, loteprednol 
0.5% (MDM) or fluorometholone 0.1% (MM). Patients with 
monovision refractive targets ($−1.0 D) were excluded 
from postoperative visual outcome calculations.
Surgical technique
Patients with significant lens opacities, keratoconus, 
unstable refraction, autoimmune disease, pregnancy or 
breastfeeding, or immunosuppressive therapy were excluded 
from treatment. Photorefractive keratectomy was performed 
in the following manner. The corneal epithelium was gently 
debrided after exposure to ethanol 20% for 30–40 seconds. 
Laser ablation was performed using the VISX Star S4 
excimer laser (VISX Incorporated, Santa Clara, CA) and 
treatments were conventional or CustomVue™. Imme-
diately after ablation, the ocular surface was rinsed with 
chilled saline for 30 seconds. This was followed by one 
drop of a topical fluoroquinolone, a topical nonsteroidal 
anti-inflammatory drug, prednisolone acetate 1%, and a 
soft bandage contact lens. One hundred and sixty of the 
579 eyes received a pledget soaked in mitomycin C 0.02% 
for 10–12 seconds after the laser ablation and before the 
balanced salt solution rinse.
Postoperative management
Patients were treated with a topical fluoroquinolone and 
prednisolone acetate 1% four times a day for one week, after 
which the regimens differed between the groups according to 
surgeon preference. Patients in the loteprednol 0.5% group 
were treated with prednisolone acetate 1% two times a day 
for three weeks followed by loteprednol 0.5% twice daily 
for one month and then daily for one month. Patients in the 
fluorometholone 0.1% group were treated with prednisolone 
acetate 1% four times a day for one month followed by 
fluorometholone 0.1% three times a day for a month, tapered 
by one drop a month.
Preoperative characteristics, including sex, age, manifest 
refraction spherical equivalent (MRSE), and postoperative 
outcomes, including uncorrected and corrected distance visual 
acuity, corneal haze, and elevated intraocular pressure, were 
compared between the two groups during the first 6 months 
after surgery. Significantly elevated postoperative intraocu-
lar pressure was defined as $25 mmHg or as $10 mmHg 
above preoperative intraocular pressure. Corneal haze was 
graded using the Fantes scale for which grade 0 = clear, grade 
0.5 = trace opacity only seen by indirect broad illumination, 
grade 1 = minimal density seen with difficulty with direct and 
diffuse illumination, grade 2 = mild haze visible with direct 
focal slit illumination, grade 3 = moderately dense opacity 
that partially obscures iris detail, and grade 4 = severely 
dense opacity that obscures intraocular structures. Statistical 
analysis was performed using parametric tests for numerical 
data and nonparametric tests for ordinal data.
Results
The fluorometholone group consisted of 273 eyes from 70 
(47.0%) males and 79 (53.0%) females. The loteprednol 
group consisted of 306 eyes from 80 (47.9%) males and 87 
(52.1%) females. The mean age was 35.5 (21–64) years and 
34.7 (21–59) years in the fluorometholone and loteprednol 
groups, respectively (P = 0.271). Mean preoperative MRSE 
was −4.03 D ± 1.92 (range −10.38 to +4.63) and −4.09 
D ± 1.97 (range −10.00 to +0.85) in the fluorometholone and 
loteprednol groups, respectively (P = 0.708, Table 1).
Haze
The fluorometholone group had 89 eyes (mean preoperative 
MRSE −5.65 D ± 1.72) treated with intraoperative mitomycin 
C and the loteprednol group had 50 eyes (mean preoperative 
MRSE −5.85 D ± 2.90, P = 0.616) treated with intraoperative 
mitomycin C. Figure 1 and Table 2 show the corneal haze 
outcomes on postoperative visits at months 1, 2, 3, and 6. For 
the purposes of our study, we defined post-photorefractive 
keratectomy corneal haze as being visually significant if it 
was associated with decreased visual acuity or subjective 
complaints by the patient. None of the eyes in the lotepred-
nol group had visually significant haze at 6 months. In the 
fluorometholone group at 6 months, only two eyes (from 
one patient) had visually significant haze. The patient had 
a preoperative MRSE of −5.75 D OD and −6.00 D OS. The 
patient was treated with intraoperative mitomycin C but was 
reported to be noncompliant with postoperative medication 
and follow-up visits. The other eyes in the fluorometholone 
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group with haze had best-corrected visual acuity of 20/20 
or better.
Intraocular pressure
Significantly elevated postoperative intraocular pressure was 
defined as $25 mmHg or as $10 mmHg above preoperative 
intraocular pressure. At one month, more patients were noted 
to have elevated intraocular pressure in the fluorometholone 
group, although this difference was not statistically signifi-
cant (P = 0.26, Chi-squared analysis), with a broad range 
of intraocular pressures measured (24–46 mmHg). It is 
important to note that the fluorometholone group was on 
prednisolone four times a day during this time, whereas the 
loteprednol group had already been tapered to prednisolone 
twice daily. Subsequently, both groups had a lower incidence 
of elevated intraocular pressure (P . 0.05 at months 2 and 3, 
Fisher’s exact test, Table 3).
Visual acuity
The mean uncorrected distance visual acuity (logMAR) was 
0.004 ± 1.4 (−0.30 to 0.70) in the fluorometholone group and 
−0.028 ± 1.1 (−0.12 to 0.40, P = 0.013) in the loteprednol 
group (Table 4). The mean postoperative corrected distance 
visual acuity (logMAR) was −0.06 ± 0.85 and −0.07 ± 0.81 in 
the fluorometholone and loteprednol groups, respectively 
(P = 0.225). The MRSE at 6 months was −0.08 D ± 0.54 
and −0.10 D ± 0.31 (P = 0.582) in the fluorometholone and 
loteprednol groups, respectively. Seventy-nine percent and 
77% of eyes in the fluorometholone and loteprednol groups 
achieved a postoperative uncorrected distance visual acuity 
Table 1 Demographic and preoperative characteristics
Demographics Fluorometholone Loteprednol
Patients (n) 149 167
Eyes (n) 273 306
Male:female 1:1 1:1
Preoperative characteristics Mean ± SD (range) Mean ± SD (range) P-value
Age (y) 35.5 ± 9.3 (21 to 64) 34.7 ± 8.2 (21 to 59) 0.271
MrSE (D) −4.03 ± 1.92 (−10.38 to 4.63) −4.09 ± 1.97 (−9.25 to 0.85) 0.708
Sphere (D) −4.52 ± 1.95 (−11.75 to 4.00) −4.52 ± 2.03 (−10.00 to 0.85) 0.988
Cylinder (D) 1.00 ± 0.91 (0.00 to 5.00) 0.90 ± 0.81 (0.00 to 4.00) 0.173
Keratometry (D) 41.12 ± 1.69 (38.20 to 47.94) 44.36 ± 1.43 (40.31 to 48.81) 0.076
Pachymetry (μm) 531 ± 31 (460 to 625) 544 ± 35 (481 to 631) 6.42 E-6
Note: Homoscedastic independent student t test.
Abbreviations: D, diopters; MrSE, manifest refraction spherical equivalent; SD, standard deviation; y, years.
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Figure 1 Percentage of eyes with haze at months 1, 2, 3, and 6 postoperatively, comparing fluorometholone versus loteprednol.
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of 20/20 or better (Figure 2). Similar safety results were 
achieved in both groups, with 6% of eyes treated with 
fluorometholone losing 1 line of corrected distance visual 
acuity compared with 4% of eyes treated with loteprednol 
(Figure 3). Eighty-nine percent of fluorometholone eyes and 
90% of loteprednol eyes achieved postoperative spherical 
equivalent refraction within 0.50 D of plano (Figure 4).
Discussion
Loteprednol is approved for the treatment of inflamma-
tory conditions of the anterior segment, including allergic 
conjunctivitis and anterior uveitis.8 Animal studies compar-
ing loteprednol with dexamethasone, prednisolone, and 
fluorometholone report loteprednol to have a smaller effect 
on intraocular pressure, with effective anti-inflammatory 
effects.9,10 Clinical studies have demonstrated clinical effi-
cacy for loteprednol, but not at the level of prednisolone.11 
The chemical structure of loteprednol lacks a ketone group 
found in other corticosteroids to be associated with cataract 
formation. Thus, loteprednol may be less cataractogenic than 
other corticosteroids.11 Like many ophthalmic medications, 
it may be used off-label and has been used in postoperative 
management of cataract surgery with success.12 The lower 
side effect profile, including a reduced likelihood of increased 
intraocular pressure, has led to its use after penetrating 
keratoplasty.13
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) Table 3 number of eyes with significant elevated intraocular 
pressure
Fluorometholone Loteprednol
1 month
   . 25 mmHg or 10 mmHg 
above preoperative IOP
1 1
  IOP 25–30 8 9
  IOP .30 5 0
  Total 14 10
  IOP range 24 to 46 24 to 27
2 months
   .25 mmHg or 10 mmHg 
above preoperative IOP
1 3
  IOP 25–30 1 0
  IOP .30 0 0
  Total 2 3
  IOP range 22 to 26 17 to 24
3 months
   .25 mmHg or 10 mmHg 
above preoperative IOP
1 0
  IOP 25–30 0 0
  IOP .30 0 0
  Total 1 0
  IOP range 24 n/A
Abbreviation: IOP, intraocular pressure.
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inflammation and maintain a low incidence of haze. This 
retrospective study evaluates the outcomes of postoperative 
treatment with loteprednol and fluorometholone.
The two treatment groups were statistically similar for 
preoperative characteristics. The corrected postoperative 
visual outcomes were also similar between the two groups; 
however, the uncorrected distance visual acuity was statis-
tically better in the loteprednol group (Figure 2, Table 4). 
Again, the retrospective nature of the study limits the ability 
to draw conclusions from this result, but at least noninferior-
ity in the loteprednol group is suggested.
Secondary outcome variables in this study were incidence 
of haze and increase in intraocular pressure. The incidence 
of post-photorefractive keratectomy haze reported in the 
literature is low, although variable. The current study lacks 
sufficient power to delineate a statistical difference in treat-
ment outcomes, given the low incidence of postphotorefractive 
Table 4 Outcomes at 6 months postoperatively
Demographics Fluorometholone Loteprednol
Patients (n) 142 153
Eyes (n) 266 291
Male:female 1:1 1:1
Postoperative outcomes Mean ± SD (range) Mean ± SD (range) P-value
MrSE (D) −0.08 ± 0.54 (−4.00 to 1.50) −0.10 ± 0.31 (−1.25 to 1.00) 0.582
Sphere (D) −0.23 ± 58 (−5.00 to 1.00) −0.24 ± 0.36 (−1.50 to 1.00) 0.753
Cylinder (D) 0.31 ± 0.35 (0.00 to 2.00) 0.29 ± 0.36 (0.00 to 1.50) 0.616
UDVA (logMAr) 0.004 ± 1.4 (−0.30 to 0.70) −0.028 ± 1.1 (−0.12 to 0.40) 0.013
UDVA (snellen) 20/20.2 (20/10 to 20/100) 20/18.7 (20/15 to 20/50) –
CDVA (logMAr) −0.060 ± 0.85 (−0.30 to 0.18) −0.070 ± 0.81 (−0.30 to 0.40) 0.225
CDVA (snellen) 20/17.4 (20/10 to 20/30) 20/17.0 (20/10 to 20/50) –
Note: Homoscedastic independent student t test.
Abbreviations: D, diopters; MrSE, manifest refraction spherical equivalent; n, number; SD, standard deviation; UDVA, uncorrected distance visual acuity; CDVA, corrected distance 
visual acuity.
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Given the controversy associated with steroid use in 
photorefractive keratectomy patients, no standard regimen 
is accepted. However, three common methods are employed, 
ie, no steroid in the absence of haze, a short course start-
ing at 4 times a day with a rapid taper over a month, and a 
long course tapered over 6 months.14 Early clinical work in 
evaluating steroid use in photorefractive keratectomy used 
corticosteroids such as dexamethasone15 or fluorometholone.1 
Prednisolone acetate is typically used postoperatively as an 
initial anti-inflammatory agent,16 which is then switched to 
a less potent steroid to minimize side effects. Although the 
risk of increased intraocular pressure with fluorometholone 
is a third that with dexamethasone,17 increased intraocular 
pressure has still been observed with its use.18
The use of loteprednol  has been considered a viable 
alternative to these other steroids in minimizing intraocular 
pressure spikes while still attempting to control postoperative 
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keratectomy haze. Even so, the incidence of haze was noted 
to be similar in the two groups throughout the postoperative 
period (Figure 1). More patients in the fluorometholone group 
(32.6%) received treatment with mitomycin C than did those 
in the loteprednol group (16.3%, P , 0.001), and the dura-
tion of prophylactic treatment with topical steroid drops 
was longer in the fluorometholone group (16 weeks as com-
pared with 12 weeks in the loteprednol group). Visible haze 
occurred at the same rate in both groups at 6 months (13% 
fluorometholone, 13% loteprednol). Future studies should 
match the use of   mitomycin C and standardize the length 
of treatment to minimize confounding variables. Lotepre-
dnol prevented haze at least as well as fluorometholone, 
despite a shorter treatment time and less frequent use of 
mitomycin C.
The steroid-induced intraocular pressure increase was 
similar in the two groups and is consistent with at least non-
inferiority of loteprednol as compared with fluorometholone. 
It is unclear whether a larger sample size would support 
previous studies, which have found a decreased intraocular 
pressure rise with use of loteprednol.6,7
An important consideration for the prescribing refractive 
surgeon is cost. Currently, fluorometholone 1% is available 
in a generic form but loteprednol is not. In surveying our 
local pharmacies, loteprednol is 3–6 times more expensive 
than generic fluorometholone. The potential benefits must 
be weighed against increased costs for patients and third-
party payers.
At our academic institution, the relative number of laser-
assisted in situ keratomileusis (LASIK) procedures has 
decreased steadily over the last 5 years, while photorefractive 
keratectomy has increased, to the point of being more com-
monly performed than LASIK for the last 2 years. With this 
resurgence of photorefractive keratectomy, it is worthwhile 
to consider optimal postoperative management of these 
patients. While this research has some limitations due to 
its retrospective nature, it is the first study to report the 
efficacy and noninferiority of loteprednol prophylaxis after 
photorefractive keratectomy. Future prospective controlled 
studies could help determine whether loteprednol has true 
advantages over traditional topical steroids.
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